Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Eisai Co., Ltd.    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Eisai : Rated 'A', the highest rating in the CDP Climate Change Report 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 09:59am EST

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') has announced that it has been selected as the highest rated company 'A' in the Climate Change Report 2019 issued by the CDP1, a non-profit organization, as a company that has performed particularly well in response to climate change.

The CDP is a non-profit organization based in London that requests top ranking market capitalization companies and municipalities in principal countries to disclose information on climate change, water and forests. After analyzing and evaluating this information, CDP discloses it to the investors, companies and government.

Based on the Eisai Network Companies (ENW) Environmental Protection Policy, all employees recognize the importance of environmental protection and conduct business operations seeking co-existence with the global environment. In particular, with regard to climate change, Eisai has positioned it as a key issues facing society, and has set the greenhouse gas emission reduction targets based on the scientific grounds approved by Science Based Targets (SBT) initiative2 in 2019, and has strengthened its commitment to that goal. In addition, Eisai addresses reduction of risk and creation of opportunity by capturing the mid- and long-term effects of climate changes to its business utilizing the framework of the Task Force on Climate-related Financial Disclosure (TCFD)3.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Under this human health care (hhc) philosophy, Eisai will strengthen its effort on climate change and contribute to ensuring the sustainability of society.

Contact:

Tel: +81-(0)3-3817-5120

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EISAI CO., LTD.
02/24EISAI : and FUJI YAKUHIN Conclude License Agreement Concerning the Development a..
AQ
02/24EISAI : Receives the president's award of the japan techno-economics society at ..
AQ
02/21EISAI : Receives the President's Award of the Japan Techno-Economics Society at ..
AQ
02/14EISAI : to Voluntarily Withdraw BELVIQ/BELVIQ XR in the U.S
AQ
02/13EISAI : Weight loss drug Belviq pulled from market over cancer risk
AQ
02/11SANOFI : From London to Kigali - We Must Embrace Change to Beat NTDs
AQ
02/11EISAI : METAvivor and Presenting Sponsor Eisai Inc. Team Up with AnaOno Intimate..
AQ
02/06BIOARCTIC PUBL : Full Year Report for the period January - December 2019
AQ
01/31EISAI : To support counter measures for china's novel coronavirus-associated pne..
AQ
01/31Astellas Pharma keeps profit forecast as prostate cancer drug sales rise
RE
More news
Financials (JPY)
Sales 2020 681 B
EBIT 2020 114 B
Net income 2020 96 973 M
Finance 2020 173 B
Yield 2020 1,81%
P/E ratio 2020 25,4x
P/E ratio 2021 33,8x
EV / Sales2020 3,41x
EV / Sales2021 3,35x
Capitalization 2 499 B
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 8 788,33  JPY
Last Close Price 8 723,00  JPY
Spread / Highest target 72,0%
Spread / Average Target 0,75%
Spread / Lowest Target -48,4%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Yasuhiko Katoh Chairman
Yasushi Okada COO, Representative Executive Officer & Head-China
Ryohei Yanagi CFO & Chief Investor Relations Officer
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD.2.06%22 697
JOHNSON & JOHNSON0.03%381 112
ROCHE HOLDING AG10.13%287 430
MERCK AND COMPANY-11.74%204 366
NOVARTIS2.72%201 414
PFIZER-11.51%187 773